Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-03
2007-04-03
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S171000, C546S172000, C514S313000, C514S314000
Reexamination Certificate
active
10817688
ABSTRACT:
The present invention relates to a novel class of hydroxamic acid derivatives having at least two aryl containing groups, at least one of which is a quinolinyl, isoquinolinyl or benzyl moiety, linked to the hydroxamic acid group through a methylene chain. The hydroxamic acid compounds can be used to treat cancer, for example, brain cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.
REFERENCES:
patent: 2279560 (1942-04-01), Dietrich
patent: 2346665 (1944-04-01), Cupery
patent: 2895991 (1959-07-01), Randall et al.
patent: 3450673 (1969-06-01), McKillip
patent: 3632783 (1972-01-01), Stonis
patent: 3875301 (1975-04-01), Windheuser
patent: 4056524 (1977-11-01), Walker
patent: 4442305 (1984-04-01), Weitl et al.
patent: 4480125 (1984-10-01), Haas
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4537781 (1985-08-01), Darling
patent: 4611053 (1986-09-01), Sasa
patent: 4614815 (1986-09-01), Cognigni et al.
patent: 4801748 (1989-01-01), Murahashi et al.
patent: 4863967 (1989-09-01), Hall et al.
patent: 4882346 (1989-11-01), Driscoll et al.
patent: 4935450 (1990-06-01), Cone, Jr.
patent: 4983636 (1991-01-01), Takeuchi et al.
patent: 5055608 (1991-10-01), Marks et al.
patent: 5175191 (1992-12-01), Marks et al.
patent: 5330744 (1994-07-01), Pontremoli et al.
patent: 5366982 (1994-11-01), Dereu et al.
patent: 5369108 (1994-11-01), Breslow et al.
patent: 5668179 (1997-09-01), Breslow et al.
patent: 5700811 (1997-12-01), Breslow et al.
patent: 5773474 (1998-06-01), Breslow et al.
patent: 5846960 (1998-12-01), Labrie
patent: 5932616 (1999-08-01), Breslow et al.
patent: 6087367 (2000-07-01), Breslow et al.
patent: 6511990 (2003-01-01), Breslow et al.
patent: 2003/0235588 (2003-12-01), Richon et al.
patent: 2004/0087657 (2004-05-01), Richon et al.
patent: 2004/0092558 (2004-05-01), Klimko et al.
patent: WO 01/18171 (2001-03-01), None
patent: WO 03/032921 (2003-04-01), None
Archer et al. (1998).PNAS 95: 6791-6796.
Brown et al. (1986).23-Aliphatics 105: 605. (FromSynth. Commun., 1985, 15: 1159-1164, Abstract No. 78501v).
Brown et al. (1986).Inorganic Chemistry 25: 3792-3796.
Chun et al. (1986).Cancer Treatment Reports 70: 991-996.
Cohen et al. (1999).Anticancer Res. 19: 4999-5006.
Curtin, M. (2002).Expert Opin. Ther. Patents 12: 1375-1384.
Das et al. (1984). “Synthesis of Some Dihydroxamic Acid Siderophores.”Chemical Abstracts 101: 582. (FromJ. Chem. Eng. Data, 1984, 29: 345-348, Abstract No. 54665t.
Dressel et al. (2000).Anticancer Res. 20: 1017-1022.
Egorin et al. (1987).Cancer Res. 47: 617-623.
Fibach et al. (1977).Cancer Res. 37: 440-444.
Finnin et al. (1999).Nature 401: 188-193.
Grunstein et al. (1997).Nature 389: 349-352.
Haces et al. (1987).J. Med. Chem. 30: 405-409.
Hozumi et al. (1979).Int. J. Cancer 123: 119-122.
Hynes, J.B. (1970).J. Medicinal Chem. 13: 1235-1237.
Iwata and Hirai “Polyurethanes with Small Permanent Comressive Strain and Their Moldings.”Chemical Abstracts 125: 28. (FromJpn. Kokai Tokkyo KohoJP 08,176,264 [96,176,263], 1996, Abstract No. 222822h.
Kijima et al. (1993).J. Biol. Chem. 268: 22429-22435.
Kim et al. (1999).Oncogene 18: 2461-2470.
Kwon et al. (1998).Proc. Natl. Acad. Sci. USA 95: 3356-3361.
Lea and Tulsyan (1995).Anticancer Res. 15: 879-883.
Lin et al. (1998).Nature 391: 811-814.
Linfield et al. (1983).J. Med. Chem. 26: 1741-1746.
Marks et al. (1978).Antibiotics Chemother. 23: 33-41.
Marks and Rifkind (1988).Int. J. of Cell Cloning 6: 230-240.
Marks et al. (1989).Proc. Natl. Acad. Sci USA 86: 6358-6362.
Melloni et al. (1988).Proc. Natl. Acad. Sci. USA 85: 3835-3839.
Morrison and Boyd “Conversion of Amines Into Substituted Amides.” InOrganic Chemistry(3rded., Allyn and Bacon, Boston, Massachusetts), pp. 755-758 (1973).
Nakajima et al. (1998).Exp. Cell Res 241: 126-133.
Prabhaker et al. (1985).Arzneim.-For-sch./Drug Res. 35: 1030-1033.
Reuben et al. (1976).Proc. Natl. Acad.Sci. USA 173: 862-866.
Reuben et al. (1978).J. Biol. Chem. 253: 4214-4218.
Reuben et al. (1980).Biochimica et Biophysica Acta 605: 325-346.
Richon et al. (1996).Proc. Natl. Acad. Sci. USA 93: 5705-5708.
Richon et al. (1998).Proc. Natl. Acad. Sci. USA 95: 3003-3007.
Rifkind and Marks (1978).Blood Cells 14: 189-206.
Saito et al. (1999).Proc. Natl. Acad. Sci. USA 96: 4592-4597.
Sof'ina et al. “Experimental Evaluation of Antitumor Drugs in the USA and USSR and Clinical Correlations.”National Cancer Institute Monograph 55, Dec. 1980. NIH Publication No. 80-1933. pp. 76-78.
Tabernero et al. (1983).1-Pharmacology 98: 27. (FromActa Cient. Venez, 32: 411-416, 1981).
Tanaka et al. (1975).Proc. Natl. Acad. Sci. USA 172: 1003-1006.
Toi and Izumi (1961).Chemical Abstract, Caold Accession No. CA55:6371e.
Van Lint et al. (1996).Gene Expression 5: 245-253.
Weitl and Raymond (1981).J. Org. Chem. 46: 5234-5237.
Yoshida et al. (1990).J. Biol. Chem. 265: 17174-17179.
Belvedere Sandro
Breslow Ronald
Marks Paul A.
Miller Thomas A.
Richon Victoria M.
Elrifi, Esq. Ivor R.
Mintz Levin Cohn Ferris Glovsky and Popeo PC
Seaman D. Margaret
Sloan-Kettering Institute for Cancer Research
The Trustees of Columbia University in the City of New York
LandOfFree
Hydroxamic acid compounds and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroxamic acid compounds and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxamic acid compounds and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3782504